Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2CNS 1

Conditions

Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Meningeal Neoplasms 1Melanoma 1Lymphoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

trastuzumab deruxtecan 1sapanisertib 1entinostat 1Temozolomide 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Leucovorin 1Immunotherapy 1Immunoglobulin G 1Floxuridine 1Fentanyl 1Drug Therapy 1Disulfides 1Biological Therapy 1Bevacizumab 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × sapanisertib × CNS × Clear all
NCT02142803 2026-04-29

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
50 enrolled 16 charts
CNSGynecologic

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡